84799-34-8

Basic information

• Product Name: (S)-Lorazepam acetate
• Synonyms: (S)-Lorazepam acetate
• CAS NO: 84799-34-8
• Molecular Formula: C17H12Cl2N2O3
• Molecular Weight: 363.19
• Mol File: 84799-34-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 524.4°C at 760 mmHg
• Flash Point: 270.9°C
• Appearance: /
• Density: 1.45g/cm³
• Vapor Pressure: 4.33E-11mmHg at 25°C
• Refractive Index: 1.656
• CAS DataBase Reference: (S)-Lorazepam acetate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-Lorazepam acetate(84799-34-8)
• EPA Substance Registry System: (S)-Lorazepam acetate(84799-34-8)

Safety Data

• Hazardous Substances Data: 84799-34-8(Hazardous Substances Data)

Usage

General Description

(S)-Lorazepam acetate is a chemical compound that is a derivative of the benzodiazepine, lorazepam. It is commonly used as a sedative and anxiolytic medication to treat anxiety disorders, insomnia, and other related psychiatric conditions. The compound works by acting on the central nervous system to produce a calming effect and reduce the symptoms of anxiety. It is typically administered orally as a tablet or liquid solution, and its effects are relatively fast-acting, making it a popular choice for managing acute anxiety episodes. However, due to its potential for abuse and addiction, (S)-Lorazepam acetate is classified as a controlled substance and should be used with caution and under the supervision of a healthcare professional.

InChI:InChI=1/C17H12Cl2N2O3/c1-9(22)24-17-16(23)20-14-7-6-10(18)8-12(14)15(21-17)11-4-2-3-5-13(11)19/h2-8,17H,1H3,(H,20,23)/t17-/m0/s1

Upstream product

• 64-19-7 acetic acid 
• 2894-67-9 delorazepam 
• 127-08-2 potassium acetate 
• 14405-03-9 2-chloroacetamido-2’,5-dichlorobenzophenone 
• 2958-36-3 (2-amino-5-chloro-phenyl)-(2-chloro-phenyl)-methanone 

Relevant articles and documents

Light-stabilized pharmaceutical composition, and preparation method and pharmaceutical application thereof

The invention relates to a light-stabilized pharmaceutical composition, and a preparation method and pharmaceutical application thereof. Specifically, the pharmaceutical composition comprises a lorazepam crystal and pharmaceutical adjuvants. The lorazepam crystal is radiated by Cu-K alpha. In a powder X-ray diffraction pattern expressed by an angle of 2 theta, there are diffraction peaks at approximately 12.17 degrees, approximately 14.15 degrees, approximately 15.27 degrees, approximately 16.84 degrees, approximately 17.91 degrees and approximately 20.81 degrees. For example, the crystal hasdiffraction peaks at approximately 7.93 degrees, approximately 9.04 degrees, approximately 12.17 degrees, approximately 14.15 degrees, approximately 15.27 degrees, approximately 16.84 degrees, approximately 17.91 degrees, approximately 20.81 degrees, approximately 21.44 degrees and approximately 26.38 degrees. A new crystal form and the pharmaceutical composition, which are used for preparing lorazepam and prepared by the method, exhibit excellent properties as described in the description of the invention.

New crystal form of lorazepam, preparation method and pharmaceutical applications thereof

The invention relates to a new crystal form for preparing lorazepam, a preparation method and pharmaceutical applications thereof, wherein specifically the lorazepam crystal has diffraction peaks at about 12.17 DEG, about 14.15 DEG, about 15.27 DEG, about 16.84 DEG, about 17.91 DEG and about 20.81 DEG in a powder X-ray diffraction pattern represented by a 2[theta] angle by using Cu-Kalpha radiation, for example, the crystal has diffraction peaks at about 7.93 DEG, about 9.04 DEG, about 12.17 DEG, about 14.15 DEG, about 15.27 DEG, about 16.84 DEG, about 17.91 DEG, about 20.81 DEG, about 21.44 DEG and about 26.38 DEG. The invention further provides a preparation method of the new crystal of larazepam, and pharmaceutical applications of the new crystal form. According to the invention, the prepared new crystal form for preparing lorazepam shows excellent properties defined in the specification.

Efficient synthesis of 3-hydroxy-1,4-benzodiazepines oxazepam and lorazepam by new acetoxylation reaction of 3-position of 1,4-benzodiazepine ring

Simple, efficient, and scalable syntheses of 3-hydroxy-1,4-benzodiazepines, oxazepam (1), and lorazepam (2) were developed. The syntheses are based on the new acetoxylation reaction of the 3-position of the 1,4-benzodiazepine ring. The reaction involves iodine (20-50 mol %)-catalyzed acetoxylation in the presence of potassium acetate (2 equiv) and potassium peroxydisulfate (1-2 equiv) as a stoichiontetric oxidant affording the corresponding 3-acetoxy-1,4- benzodiazepines in good-to-high yields. The latter were converted by selective saponification to 3-hydroxy-1,4-benzodiazepines of very high purity (>99.8%) in an overall yield of 83% (oxazepam) and 64% (lorazepam).